Novartis drug cuts recurrence risk by 25% in early-stage breast cancer, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

Kisqali was used in the trial together with standard endocrine therapy to treat a type of cancer that grows in response to hormones and it was compared to endocrine therapy alone. Novartis in March gave a brief preview of the Kisqali data, boosting its shares and growth prospects., Kisqali was used in the trial together with standard endocrine therapy to treat a type of cancer that grows in response to hormones and it was compared to endocrine therapy alone. Novartis in March gave a brief preview of the Kisqali data, boosting its shares and growth prospects., , Read More